Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses

Depression is a common comorbid condition in Parkinson’s disease (PD). Patients with depression have a two-fold increased risk to develop PD. Further, depression symptoms often precede motor symptoms in PD and are frequent at all stages of the disease. However, the influence of a depressive state on...

Full description

Bibliographic Details
Main Authors: Nicoletta Schintu, Xiaoqun Zhang, Nikolas Stroth, Aleksander A. Mathé, Per E. Andrén, Per Svenningsson
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-03-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00304/full
id doaj-c42b5cd8e5b84b14ab644ee89d631dd2
record_format Article
spelling doaj-c42b5cd8e5b84b14ab644ee89d631dd22020-11-25T03:32:11ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-03-011110.3389/fphar.2020.00304485960Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA ResponsesNicoletta Schintu0Xiaoqun Zhang1Nikolas Stroth2Aleksander A. Mathé3Per E. Andrén4Per E. Andrén5Per Svenningsson6Department of Clinical Neuroscience, Karolinska University Hospital, Karolinska Institutet, Stockholm, SwedenDepartment of Clinical Neuroscience, Karolinska University Hospital, Karolinska Institutet, Stockholm, SwedenDepartment of Clinical Neuroscience, Karolinska University Hospital, Karolinska Institutet, Stockholm, SwedenDepartment of Clinical Neuroscience, Karolinska University Hospital, Karolinska Institutet, Stockholm, SwedenMedical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, SwedenScience for Life Laboratory, Uppsala University, Uppsala, SwedenDepartment of Clinical Neuroscience, Karolinska University Hospital, Karolinska Institutet, Stockholm, SwedenDepression is a common comorbid condition in Parkinson’s disease (PD). Patients with depression have a two-fold increased risk to develop PD. Further, depression symptoms often precede motor symptoms in PD and are frequent at all stages of the disease. However, the influence of a depressive state on the responses to antiparkinson treatments is largely unknown. In this study, the genetically inbred depression-like flinders sensitive line (FSL) rats and control flinders resistant line (FRL) rats were studied in models of experimental parkinsonism. FSL rats showed a potentiated tremorgenic response to tacrine, a cholinesterase inhibitor used experimentally to induce 6 Hz resting tremor reminiscent of parkinsonian tremor. We also studied rats lesioned with 6-OHDA to induce hemiparkinsonism. No baseline differences in dopaminergic response to acute apomorphine or L-DOPA was found. However, following chronic treatment with L-DOPA, FRL rats developed sensitization of turning and abnormal involuntary movements (AIMs); these effects were counteracted by the anti-dyskinetic 5-HT1A agonist/D2 partial agonist sarizotan. In contrast, FSL rats did not develop sensitization of turning and only minor AIMs in response to L-DOPA treatment. The roles of several non-dopamine systems underlying this discrepancy were studied. Unexpectedly, no differences of opioid neuropeptides or serotonin markers were found between FRL and FSL rats. The marked behavioral difference between the FRL and FSL rats was paralleled with the striatal expression of the established marker, c-fos, but also the GABAergic transporter (vGAT), and a hitherto unknown marker, tamalin, that is known to regulate mGluR5 receptor function and postsynaptic organization. This study demonstrates that behavioral and transcriptional responses of non-dopaminergic systems to experimental parkinsonism and L-DOPA are modified in a genetic rat model of depression.https://www.frontiersin.org/article/10.3389/fphar.2020.00304/fullflinders sensitive lineParkinson’s diseaseL-DOPAdyskinesiatremortamalin
collection DOAJ
language English
format Article
sources DOAJ
author Nicoletta Schintu
Xiaoqun Zhang
Nikolas Stroth
Aleksander A. Mathé
Per E. Andrén
Per E. Andrén
Per Svenningsson
spellingShingle Nicoletta Schintu
Xiaoqun Zhang
Nikolas Stroth
Aleksander A. Mathé
Per E. Andrén
Per E. Andrén
Per Svenningsson
Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
Frontiers in Pharmacology
flinders sensitive line
Parkinson’s disease
L-DOPA
dyskinesia
tremor
tamalin
author_facet Nicoletta Schintu
Xiaoqun Zhang
Nikolas Stroth
Aleksander A. Mathé
Per E. Andrén
Per E. Andrén
Per Svenningsson
author_sort Nicoletta Schintu
title Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
title_short Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
title_full Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
title_fullStr Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
title_full_unstemmed Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
title_sort non-dopaminergic alterations in depression-like fsl rats in experimental parkinsonism and l-dopa responses
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2020-03-01
description Depression is a common comorbid condition in Parkinson’s disease (PD). Patients with depression have a two-fold increased risk to develop PD. Further, depression symptoms often precede motor symptoms in PD and are frequent at all stages of the disease. However, the influence of a depressive state on the responses to antiparkinson treatments is largely unknown. In this study, the genetically inbred depression-like flinders sensitive line (FSL) rats and control flinders resistant line (FRL) rats were studied in models of experimental parkinsonism. FSL rats showed a potentiated tremorgenic response to tacrine, a cholinesterase inhibitor used experimentally to induce 6 Hz resting tremor reminiscent of parkinsonian tremor. We also studied rats lesioned with 6-OHDA to induce hemiparkinsonism. No baseline differences in dopaminergic response to acute apomorphine or L-DOPA was found. However, following chronic treatment with L-DOPA, FRL rats developed sensitization of turning and abnormal involuntary movements (AIMs); these effects were counteracted by the anti-dyskinetic 5-HT1A agonist/D2 partial agonist sarizotan. In contrast, FSL rats did not develop sensitization of turning and only minor AIMs in response to L-DOPA treatment. The roles of several non-dopamine systems underlying this discrepancy were studied. Unexpectedly, no differences of opioid neuropeptides or serotonin markers were found between FRL and FSL rats. The marked behavioral difference between the FRL and FSL rats was paralleled with the striatal expression of the established marker, c-fos, but also the GABAergic transporter (vGAT), and a hitherto unknown marker, tamalin, that is known to regulate mGluR5 receptor function and postsynaptic organization. This study demonstrates that behavioral and transcriptional responses of non-dopaminergic systems to experimental parkinsonism and L-DOPA are modified in a genetic rat model of depression.
topic flinders sensitive line
Parkinson’s disease
L-DOPA
dyskinesia
tremor
tamalin
url https://www.frontiersin.org/article/10.3389/fphar.2020.00304/full
work_keys_str_mv AT nicolettaschintu nondopaminergicalterationsindepressionlikefslratsinexperimentalparkinsonismandldoparesponses
AT xiaoqunzhang nondopaminergicalterationsindepressionlikefslratsinexperimentalparkinsonismandldoparesponses
AT nikolasstroth nondopaminergicalterationsindepressionlikefslratsinexperimentalparkinsonismandldoparesponses
AT aleksanderamathe nondopaminergicalterationsindepressionlikefslratsinexperimentalparkinsonismandldoparesponses
AT pereandren nondopaminergicalterationsindepressionlikefslratsinexperimentalparkinsonismandldoparesponses
AT pereandren nondopaminergicalterationsindepressionlikefslratsinexperimentalparkinsonismandldoparesponses
AT persvenningsson nondopaminergicalterationsindepressionlikefslratsinexperimentalparkinsonismandldoparesponses
_version_ 1724569068834390016